

RECEIVED CENTRAL FAX CENTER OCT 0 9 2007

## **FACSIMILE TRANSMISSION**

DATE: OCTOBER 9, 2007

PAGE 1 OF: 2:1

To: USPTO

FACSIMILE No.: (571) 273-8300

FROM: DAVID W. OSBORNE

TRANSMITTED BY: JUDY ANDERSON

OUR DOCKET No.: 01235-22619.CIP (FORMERLY 22619.CIP)

FOR: PHARMACEUTICAL FORMULATIONS & SYSTEMS FOR IMPROVED

ABSORPTION & MULTISTAGE RELEASE OF ACTIVE AGENT

SUBJECT: AMENDMENT UNDER 37 C.F.R. § 1.111 Substance of the Interview Under

1.133(b)

Commissioner For Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam:

Attached please find an Amendment under 37 C.F.R. §1.111 Substance of the Interview Under 1.133(b) for Docket No. 01235-22619.CIP (formerly 22619.CIP), Application No. 10/074,687

Thank you. We await your confirmation of receipt.

Respectfully submitted.

Dávid W. Osborne

THORPE NORTH & WESTERN, LLP

Customer No. 20,551

Reg. No.44,989

DO/SS:ja

The pages that follow may contain sensitive, privileged or confidential information intended solely for the addressee named above. If you receive this message and are not the agent or employee of the addressee, and have therefore been sent or received this communication in error, you are asked not to disseminate or copy any of the attached and are to notify the sender immediately by telephone. Please also return the original message to the sender by mail. Thank you. www.tnw.com

8180 South 700 East - Sulta 200 - Sandy, Utah 84070-0562 - 801.566.6633 - f. 801.566.0750 - patlaw@triw.com U.S. Mailing Address: P.O. Box 1219 - Sandy, Utah 84091-1218 The Team Approach to Premier Performance®

New Docket No. 01235-22619.CIP; Old Docket No. 22619.CIP Serial No. 10/074,687

22619.CIP

1

RECEIVED CENTRAL FAX CENTER

OCT 0 9 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Feng-Jing Chen, et al. CERTIFICATE OF DEPOSIT UNDER 37 C.F.R. § 1.8 SERIAL NO.: 10/074,687 I hereby certify that this correspondence is being FILING DATE: 2/11/2002 . transmitted via facsimile to the United States Patent and Trademark Office, under 37 FOR: PHARMACEUTICAL C.F.R. § 1.8 on the date FORMULATIONS AND SYSTEMS indicated below to 571-273-FOR IMPROVED ABSORPTION 8300. AND MULTISTAGE RELEASE OF **ACTIVE AGENTS** Jedy Anderson ART UNIT: 1615 Date of Deposit 10/9/2007 **EXAMINER:** Lakshmi Channavajjala

> THORPE NORTH & WESTERN, LLP 8180 South 700 East, Suite 350 Sandy, Utah 84070

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111 SUBSTANCE OF THE INTERVIEW UNDER 1.133(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DOCKET NO.:

Sir:

In response to the communication mailed August 9, 2007, please enter the amendments and reconsider this application in view of the remarks provided below.

New Docket No. 01235-22619.CIP; Old Docket No. 22619.CIP Serial No. 10/074,687 RECEIVED CENTRAL FAX CENTER

2

OCT 0 9 2007

## **INTERVIEW SUMMARY**

An telephonic interview was held between Applicant's representative and the Examiner on October 4, 2007. During the interview claims 146-233 were discussed. Specifically, the possibility of amending claims 146 and 193 to clarify any ambiguity in support for the amendment made in the previously presented claims. Support for such an amendment was also shown and discussed, and it was agreed that the amendments appearing below placed the claims in condition for allowance.